

## Format for ANSWERING REVIEWERS

August 25, 2012

Dear Editor,



Please find enclosed the edited manuscript in Word format (file name : WJOG1472-revised).

**Title:** Pharmacology of Cancer Chemotherapy Drugs for Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) in Epithelial Ovarian Cancer

**Author:** Kurt Van der Speeten, Oscar Anthony Stuart, Paul Henri Sugarbaker

**Name of Journal:** *World Journal of Obstetrics Gynaecology*

**ESPS Manuscript NO:** 1472

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

- (1) Category was specified in the introduction : topic highlight ( one of the manuscript categories specified in the instructions for the author).
- (2) The review search strategy for this topic highlight manuscript was clarified in the introduction.
- (3) Page 6, line 8 was unclear as pointed out by the reviewer. It was rephrased: ' The intraperitoneal route of delivering chemotherapy is logistically less convenient and technologically more challenging than conventional intravenous chemotherapy. This explains why the pharmacokinetic rationale of intraperitoneal chemotherapy needs to be clarified to justify this route of cancer chemotherapy administration.'
- (4) As requested, the references at the top of page 7 were reviewed.
- (5) On page 8 after the sentence ' Hoskins et al....' the source data and statistics from the GOG trials and the Deutsche Arbeitsgemeinschaft trial were introduced in the manuscript.
- (6) Comment about reference 72 at page 14: Elias et al. The reviewer asks about results and survival benefit in this reference. As this reference is a pharmacokinetic article, it doesn't provide us with these data.
- (7) A separate heading on controversies and future directions was included to address the concern of the reviewers on potential limitations and opportunities for both intravenous and intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer

.....

Thank you again for considering our manuscript.

Sincerely yours,

Kurt Van der Speeten, MD, PhD